HER2+ Breast Cancer: Anthracycline Considerations

EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer

Now Viewing

EP: 3.HER2+ Breast Cancer: Anthracycline Considerations

EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends

EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer

EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer

EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer

EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights

EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges

EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer

EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

The panel discusses the use of anthracyclines in patients with HER2-positive breast cancer treatment. Rugo raises the complexity of determining whether patients need anthracyclines, particularly in cases where there’s extensive residual disease after TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) therapy. O’Shaughnessy highlights the challenge of managing tumors with heterogeneity and true biphenotypic cancers, emphasizing the importance of accurate HER2 testing and considering a preoperative AC (doxorubicin, cyclophosphamide) regimen in certain scenarios. Sharma notes situations where AC might be considered, such as when the patient has baseline peripheral neuropathy or if there are concerns about the patient completing 6 cycles of taxane-based therapy. Isaacs mentions cases with bilateral disease exhibiting different characteristics where anthracyclines may provide broader coverage. The discussion emphasizes personalized approaches, taking into account individual patient factors and tumor characteristics to optimize the treatment of patients with HER2-positive breast cancer.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.